EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
45
PAGES
762
EDITION
4
PRICE
USD 5800
CODE
MCP16937
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global COVID-19 Vaccines Market to Reach $60.7 Billion by 2025
Annual Doses of COVID-19 Vaccines estimated at US$255 Million in the year 2020, is projected to reach US$60.7 Billion by 2025. Value of annual doses in China is forecast to stabilize to US$23 billion by 2025, after peaking at US$73 billion in the year 2021. Global percentage of individuals vaccinated by the year 2025 is expected to taper down to 47% by the year 2025 as compared to the 73% estimated for the year 2022.
Vaccinated population in Africa will reach only 12% by the year 2023, a figure that will dwindle to 4% by 2025. In comparison, the percentage of individuals vaccinated in France is expected to touch 92% by the end of 2022. Number of doses administered worldwide is expected to rise to 4,186 million by 2025.
SELECT PLAYERS
AstraZeneca PLC; Aurobindo Pharma Ltd.; Amyris, Inc.; AnGes, Inc.; Altimmune, Inc.; Arcturus Therapeutics, Inc.; ADImmune Corporation; AdaptVac; AJ Vaccines; Batavia Biosciences BV; ARTES Biotechnology GmbH; Baylor College of Medicine; baseclick GmbH; Barcelona Supercomputing Center; Akston Biosciences Corporation
SEGMENTS
» Age Group (18 Years & Above, Under 18 Years)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » India » Rest of Asia-Pacific » Latin America » Brazil » Mexico » Rest of Latin America » Middle East » Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic |
| EXHIBIT 2: Time is of Essence! What We Know So Far – “Vaccine Efficiency Against New Strains is Decreasing” |
| South Africa: Omicron’s Origin Location |
| Omicron: Impact on Travel Industry |
| Countries that have Already Detected Omicron Cases |
| Steps taken by the Countries to Prevent Transmission of Omicron Variant |
| Fears of Tourism Industry |
| Industry Response to the Travel Curbs |
| Short-term Impact of Omicron on Travel |
| Financial Impact |
| Scientists Seek to Gather More Information on Omicron |
| Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron |
| With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? |
| EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness, but this Strategy is Not Within Reach for Most Countries: Number of Booster Doses Administered Per 100 People by Country as of December 2021 |
| At the Dawn of 2022, We Leave Behind Millions of Deaths Due to New Strains & Once Again Stare at an Impending Catastrophe |
| Split Scenarios Unfold: The Great Vaccine Divide Emerges |
| Amid this Prolonged Pandemic, Why Should Businesses Care About Progress on Vaccinations? |
| With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic |
| Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals |
| COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots |
| Are COVID-19 Boosters Going to Follow Flu Shot Pattern? |
| Covid-19 Vaccine Shortages Hit Global Supply Initiative |
| Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target |
| Anti-Vaccine Movement Poses Significant Threat |
| COVID-19 Vaccines – Global Key Competitors Percentage Market Share in 2022 (E) |
| THE VARIOUS COVID-19 VIRUS VARIANTS |
| Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals |
| COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots |
| Are COVID-19 Boosters Going to Follow Flu Shot Pattern? |
| Covid-19 Vaccine Shortages Hit Global Supply Initiative |
| Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target |
| Anti-Vaccine Movement Poses Significant Threat |
| EXHIBIT 5: COVID-19 Cases Worldwide by Country: As on November 21, 2021 |
| THE VARIOUS COVID-19 VIRUS VARIANTS |
| Emergence of Delta Variant Sparks New Wave of Infections |
| Is South African Variant a Formidable Threat? |
| E484K Mutation Challenges Vaccine Developers |
| California Strain Emerges to be More Contagious and Deadly |
| Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines? |
| Less Effectiveness of AstraZeneca Vaccine Against South African Variant Leads to its Halt |
| Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant |
| US Government Unveils Covid-19 Vaccine Booster Shot Plan to Maximize Vaccine Protection Against Emerging Variants |
| AstraZeneca Vaccine Effective against New Emerging Variants |
| Sinovac Vaccines Effective against Mutated Variants of Coronavirus |
| AN OVERVIEW OF COVID-19 VACCINE ROLLOUT |
| COVID-19 Vaccine Approval Details |
| EXHIBIT 8: Production Capacity by Company for Frontrunners in Millions of Doses for 2021 |
| COVID-19 Vaccine Funding Details |
| Pfizer/BioNTech’s COVID-19 Vaccine Receives World’s First Authorization |
| UK Clinches the First Position in the World to Approve Pfizer’s Vaccine |
| After UK, Pfizer’s Vaccine Gains Approval from the US and EU |
| UK Clinches the First Position in the World to Approve Pfizer’s Vaccine |
| After UK, Pfizer’s Vaccine Gains Approval from the US and EU |
| Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production |
| After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA |
| Moderna Kick-Starts Inoculation in the US |
| AstraZeneca’s Vaccine - Third Globally to Obtain Approval |
| J&J’s Single Shot Vaccination Resumes after Temporary Suspension |
| Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine |
| A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine |
| Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer |
| Russia Commences Mass Vaccination from Mid-December, 2020 |
| China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm |
| WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use |
| China Issues License for Vaccine Production to Overseas Partners |
| Brazilian Authorities Approve Sinovac’s CoronaVac |
| AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India |
| Sanofi-GSK to Offer Vaccine at a Discounted Rate |
| CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine |
| Novavax Obtains First Authorization for its COVID-19 vaccine |
| VARIOUS COVID-19 VACCINES UNDER CLINICAL TRIALS |
| EXHIBIT 9: COVID-19 VACCINES UNDER DEVELOPMENT |
| EXHIBIT 11: Vaccines in Pipeline by Technology |
| EXHIBIT 12: Vaccine Technologies in Pre-Clinical Studies |
| mRNA: A NEW APPROACH TO MEDICINE |
| mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies |
| RNA Technology: Benefits & Potential for Future Outbreaks |
| Key Challenges |
| mRNA Vaccines Could Vanquish COVID-19 and Cancer |
| Efforts to Target New Application Areas |
| MARKET DYNAMICS |
| Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions & Ensure Public Safety |
| Developments Regarding Digital Certificates |
| COVID-19 Vaccine Passport: Insights & Progress |
| mRNA Vaccines Offer More Protection Against Newer Variants |
| Vaccine Companies Stress on Booster Dose |
| Longer Interval between the Two Doses of Pfizer Vaccine to Boost Antibody Levels |
| Mix and Match is the New COVID-19 Vaccine Mantra |
| Long-Haul COVID-19 Holds Potential to Become a Public Health Issue |
| Vaccine Alliances Ensure Supplies for All |
| EXHIBIT 13: Select Funding Deals for COVID-19 Vaccine R&D: 2020 & 2021 |
| Licensing and Partnership Deals Worldwide Propel Vaccine Production |
| EXHIBIT 14: COVID-19 Deals Worldwide - Jan 2020 to July 2021 |
| GLOBAL MARKET PERSPECTIVE |
| EXHIBIT 15: Global Percentage of Individuals Vaccinated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025 |
| EXHIBIT 16: European Percentage of Individuals Vaccinated by Geographic Region - France, Germany, United Kingdom, Italy, Russia, Spain, and Rest of European Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025 |
| EXHIBIT 17: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets |
| EXHIBIT 18: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| EXHIBIT 19: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025 |
| EXHIBIT 20: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| VACCINES FOR KIDS |
| Kids: A Key to COVID-19 Controlling Efforts |
| US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age |
| Pfizer Approves Vaccine for Kids Aged 5-11 Years |
| Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021) |
| Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns |
| COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU |
| REGIONAL MARKET PERSPECTIVE |
| THE UNITED STATES |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| CANADA |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| JAPAN |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| CHINA |
| MARKET ANALYSIS |
| MARK¬ET ANALYTICS |
| EUROPE |
| Covid-19 Scenario in Europe, Rise in Cases Noted |
| New Covid-19 Variants |
| Skepticism Regarding the Vaccination |
| Europe Witnesses Increase in COVID-19 Cases, Turns to Booster Doses |
| EMA Approves Use of COVID-19 Vaccine of Pfizer for Children |
| EU to Recommend 9-MonthTime Limit for COVID-19 Vaccine Validity for Travelers |
| EU Digital COVID Certificate Regulation to Aid Free Cross-Border Movement |
| EU Digital COVID Certificate: Eligibility, Process & Free Movement |
| Pfizer & Moderna Escalate Unit Price of COVID-19 Vaccines in Latest EU Contracts |
| EU Obtains 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine |
| European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines |
| BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU |
| Europe’s Horizon 2020 |
| EC-AstraZeneca Settlement Deal Ends Legal Dispute over COVID-19 Vaccine Supplies |
| Johnson & Johnson to Resume Shipment of Janssen COVID-19 Vaccine to Europe |
| Apparent Side-Effects Prompt Denmark to Extend Suspension of Oxford-AstraZeneca COVID-19 Vaccine |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| ASIA-PACIFIC |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| THE MIDDLE EAST |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| AFRICA |
| MARKET ANALYSIS |
| SOUTH AFRICA |
| EGYPT |
| MARKET ANALYTICS |
| LATIN AMERICA |
| MARKET ANALYSIS |
| MARKET ANALYTICS |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| FOCUS ON THE FRONTRUNNERS |
| Moderna, Inc. (USA) |
| Pfizer Inc./BioNTech (US/Germany) |
| AstraZeneca/University of Oxford (The UK) |
| Johnson & Johnson (USA) |
| CanSino Biologics, Inc. (China) |
| China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China) |
| Sinovac Biotech Ltd. (China) |
| Novavax, Inc. (USA) |
| Inovio Pharmaceuticals (USA) |
| Sanofi/GlaxoSmithKline (France/UK) |
| INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES |
| Fair Distribution of COVID-19 Vaccine |
| Vaccine Nationalism Hampers Equitable Distribution of Vaccines |
| COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine |
| COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines |
| African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines |
| COVAX Advance Market Commitment (AMC) |
| World Economic Forum to Push COVID-19 Vaccine Production Capability |
| Pushing Manufacturing Capacity to Fulfil Global Demand |
| Technology Transfer and Other Payments |
| KEY VACCINE TECHNOLOGY PLATFORMS |
| Inactivated Vaccines |
| Inactivated Vaccine Candidate in Preclinical Development: As on Nov 19, 2021 |
| Protein-Subunit Vaccines |
| Protein-Subunit Vaccine Candidate in Preclinical Development: As on Nov 19, 2021 |
| Non-Replicating Viral-Vector |
| Non-Replicating Viral Vector Vaccine in Preclinical Development: As on Nov 19, 2021 |
| Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on Nov 19, 2021 |
| Nucleic Acid Vaccines |
| RNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021 |
| DNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021 |
| Replicating Bacteria Vector |
| Live Attenuated Vaccines (LAVs) |
| Live Attenuated Virus Candidate in Preclinical Studies: As on Nov 19, 2021 |
| Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on Nov 19, 2021 |
| Virus-like Particle Vaccines |
| Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on July 27, 2021 |
| WORLD COVID-19 VACCINE BRANDS |
| SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com